Journal of Medicinal Chemistry
Article
(21) Crumrine, R. C.; Bergstrand, K.; Cooper, A. T.; Faison, W. L.;
Cooper, B. R. Lamotrigine protects hippocampal CA1 neurons from
ischemic damage after cardiac arrest. Stroke 1997, 28, 2230−2236.
(22) Fujitani, T.; Adachi, N.; Miyazaki, H.; Liu, K.; Nakamura, Y.;
Kataoka, K.; Arai, T. Lidocaine protects hippocampal neurons against
ischemic damage by preventing increase of extracellular excitatory
amino acids: A microdialysis study in Mongolian gerbils. Neurosci. Lett.
1994, 179, 91−94.
(23) Graham, S. H.; Chen, J.; Lan, J.; Leach, M. J.; Simon, R. P.
Neuroprotective effects of a use-dependent blocker of voltage-
dependent sodium channels, BW619C89, in rat middle cerebral artery
occlusion. J. Pharmacol. Exp. Ther. 1994, 269, 854−859.
(24) Lekieffre, D.; Meldrum, B. S. The pyrimidine-derivative,
BW1003C87, protects CA1 and striatal neurons following transient
severe forebrain ischaemia in rats. A microdialysis and histological
study. Neuroscience 1993, 56, 93−99.
(25) Cheng, Y. D.; Al-Khoury, L.; Zivin, J. A. Neuroprotection for
ischemic stroke: Two decades of success and failure. NeuroRx 2004, 1,
36−45.
(26) Onteniente, B.; Rasika, S.; Benchoua, A.; Guegan, C. Molecular
pathways in cerebral ischemia: Cues to novel therapeutic strategies.
Mol. Neurobiol. 2003, 27, 33−72.
(27) Kapoor, R.; Furby, J.; Hayton, T.; Smith, K. J.; Altmann, D. R.;
Brenner, R.; Chataway, J.; Hughes, R. A.; Miller, D. H. Lamotrigine for
neuroprotection in secondary progressive multiple sclerosis: A
randomised, double-blind, placebo-controlled, parallel-group trial.
Lancet Neurol. 2010, 9, 681−688.
(28) Van der Walt, A.; Butzkueven, H.; Kolbe, S.; Marriott, M.;
Alexandrou, E.; Gresle, M.; Egan, G.; Kilpatrick, T. Neuroprotection in
multiple sclerosis: A therapeutic challenge for the next decade.
Pharmacol. Ther. 2010, 126, 82−93.
(29) Yu, F. H.; Catterall, W. A. Overview of the voltage-gated sodium
channel family. Genome Biol. 2003, 4, 207.
(30) Whitaker, W. R.; Faull, R. L.; Waldvogel, H. J.; Plumpton, C. J.;
Emson, P. C.; Clare, J. J. Comparative distribution of voltage-gated
sodium channel proteins in human brain. Brain Res. 2001, 88, 37−53.
(31) Kaplan, M. R.; Cho, M. H.; Ullian, E. M.; Isom, L. L.; Levinson,
S. R.; Barres, B. A. Differential control of clustering of the sodium
channels Na(v)1.2 and Na(v)1.6 at developing CNS nodes of Ranvier.
Neuron 2001, 30, 105−119.
(32) Mao, Q.; Jia, F.; Zhang, X. H.; Qiu, Y. M.; Ge, J. W.; Bao, W. J.;
Luo, Q. Z.; Jiang, J. Y. The up-regulation of voltage-gated sodium
channel Nav1.6 expression following fluid percussion traumatic brain
injury in rats. Neurosurgery 2010, 66, 1134−1139.
(33) Waxman, S. G. Axonal conduction and injury in multiple
sclerosis: The role of sodium channels. Nat. Rev. Neurosci. 2006, 7,
932−941.
(34) Yuen, T. J.; Browne, K. D.; Iwata, A.; Smith, D. H. Sodium
channelopathy induced by mild axonal trauma worsens outcome after
a repeat injury. J. Neurosci. Res. 2009, 87, 3620−3625.
(35) Wang, J. A.; Lin, W.; Morris, T.; Banderali, U.; Juranka, P. F.;
Morris, C. E. Membrane trauma and Na+ leak from Nav1.6 channels.
Am. J. Physiol.: Cell Physiol. 2009, 297, C823−C834.
(36) Boucher, P. A.; Joos, B.; Morris, C. E. Coupled left-shift of Nav
channels: Modeling the Na+-loading and dysfunctional excitability of
damaged axons. J. Comput. Neurosci. 2012, 33, 301−319.
(37) Yao, C.; Williams, A. J.; Cui, P.; Berti, R.; Hunter, J. C.; Tortella,
F. C.; Dave, J. R. Differential pattern of expression of voltage-gated
sodium channel genes following ischemic brain injury in rats.
Neurotoxic. Res. 2002, 4, 67−75.
REFERENCES
■
(1) Tarnawa, I.; Bolcskei, H.; Kocsis, P. Blockers of voltage-gated
sodium channels for the treatment of central nervous system diseases.
Recent Pat. CNS Drug Discovery 2007, 2, 57−78.
(2) Mantegazza, M.; Curia, G.; Biagini, G.; Ragsdale, D. S.; Avoli, M.
Voltage-gated sodium channels as therapeutic targets in epilepsy and
other neurological disorders. Lancet Neurol. 2010, 9, 413−424.
(3) Choi, H.; Morrell, M. J. Review of lamotrigine and its clinical
applications in epilepsy. Expert Opin. Pharmacother. 2003, 4, 243−251.
(4) Ambrosio, A. F.; Soares-Da-Silva, P.; Carvalho, C. M.; Carvalho,
A. P. Mechanisms of action of carbamazepine and its derivatives,
oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 2002, 27,
121−130.
(5) Errington, A. C.; Stohr, T.; Heers, C.; Lees, G. The
investigational anticonvulsant lacosamide selectively enhances slow
inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008,
73, 157−169.
(6) Catterall, W. A. Voltage-gated sodium channels at 60: Structure,
function and pathophysiology. J. Physiol. 2012, 590, 2577−2589.
(7) Payandeh, J.; Gamal El-Din, T. M.; Scheuer, T.; Zheng, N.;
Catterall, W. A. Crystal structure of a voltage-gated sodium channel in
two potentially inactivated states. Nature 2012, 486, 135−139.
(8) Payandeh, J.; Scheuer, T.; Zheng, N.; Catterall, W. A. The crystal
structure of a voltage-gated sodium channel. Nature 2011, 475, 353−
358.
(9) Ulbricht, W. Sodium channel inactivation: Molecular determi-
nants and modulation. Physiol. Rev. 2005, 85, 1271−1301.
(10) Lai, J.; Hunter, J. C.; Porreca, F. The role of voltage-gated
sodium channels in neuropathic pain. Curr. Opin. Neurobiol. 2003, 13,
291−297.
(11) Wood, J. N.; Boorman, J. Voltage-gated sodium channel
blockers; target validation and therapeutic potential. Curr. Top. Med.
Chem. 2005, 5, 529−537.
(12) Costigan, M.; Scholz, J.; Woolf, C. J. Neuropathic pain: A
maladaptive response of the nervous system to damage. Annu. Rev.
Neurosci. 2009, 32, 1−32.
(13) Dib-Hajj, S. D.; Black, J. A.; Waxman, S. G. Voltage-gated
sodium channels: Therapeutic targets for pain. Pain Med. 2009, 10,
1260−1269.
(14) Theile, J. W.; Cummins, T. R. Recent developments regarding
voltage-gated sodium channel blockers for the treatment of inherited
and acquired neuropathic pain syndromes. Front. Pharmacol. 2011, 2,
54.
(15) Zuliani, V.; Rivara, M.; Fantini, M.; Costantino, G. Sodium
channel blockers for neuropathic pain. Expert Opin. Ther. Pat. 2010,
20, 755−779.
(16) Hoyt, S. B.; London, C.; Gorin, D.; Wyvratt, M. J.; Fisher, M.
H.; Abbadie, C.; Felix, J. P.; Garcia, M. L.; Li, X.; Lyons, K. A.;
McGowan, E.; MacIntyre, D. E.; Martin, W. J.; Priest, B. T.; Ritter, A.;
Smith, M. M.; Warren, V. A.; Williams, B. S.; Kaczorowski, G. J.;
Parsons, W. H. Discovery of a novel class of benzazepinone Nav1.7
blockers: Potential treatments for neuropathic pain. Bioorg. Med. Chem.
Lett. 2007, 17, 4630−4634.
(17) Hoyt, S. B.; London, C.; Abbadie, C.; Felix, J. P.; Garcia, M. L.;
Jochnowitz, N.; Karanam, B. V.; Li, X.; Lyons, K. A.; McGowan, E.;
Priest, B. T.; Smith, M. M.; Warren, V. A.; Thomas-Fowlkes, B. S.;
Kaczorowski, G. J.; Duffy, J. L. A novel benzazepinone sodium channel
blocker with oral efficacy in a rat model of neuropathic pain. Bioorg.
Med. Chem. Lett. 2013, 23, 3640−3645.
(18) Waxman, S. G. Mechanisms of disease: Sodium channels and
neuroprotection in multiple sclerosis-current status. Nat. Clin. Pract.
Neurol. 2008, 4, 159−169.
(38) Huang, X. J.; Mao, Q.; Lin, Y.; Feng, J. F.; Jiang, J. Y. Expression
of voltage-gated sodium channel Nav1.3 is associated with severity of
traumatic brain injury in adult rats. J. Neurotrauma 2013, 30, 39−46.
(39) Clutterbuck, L. A.; Posada, C. G.; Visintin, C.; Riddall, D. R.;
Lancaster, B.; Gane, P. J.; Garthwaite, J.; Selwood, D. L.
Oxadiazolylindazole sodium channel modulators are neuroprotective
toward hippocampal neurones. J. Med. Chem. 2009, 52, 2694−2707.
(19) Mongin, A. A. Disruption of ionic and cell volume homeostasis
in cerebral ischemia: The perfect storm. Pathophysiology 2007, 14,
183−193.
(20) Stankowski, J. N.; Gupta, R. Therapeutic targets for neuro-
protection in acute ischemic stroke: Lost in translation? Antioxid.
Redox Signaling 2011, 14, 1841−1851.
2951
dx.doi.org/10.1021/jm401881q | J. Med. Chem. 2014, 57, 2942−2952